Objective To compare and analyze the efficacy and safety of docetaxelcontaining doublet regimen or triplet regimen as the firstline chemotherapy for Chinese patients with advanced gastric cancer. Methods Forty-six advanced gastric cancer patients without chemotherapy as initial treatment were enrolled from January 2009 to January 2012. Twenty patients received modification DCF regimen（docetaxel 30mg／m2 iv，d1，d8；cisplatin 20mg iv，d1-d5；flurouracil 500mg／m2iv，d1-d5；every 3 weeks was a cycle）. Twenty-six patients received double DC／DF regimen（docetaxel 37.5mg／m2 iv，d1，d8；cisplatin 20mg iv or flurouracil 500mg／m2 iv，d1-d5； every 3 weeks was a cycle）. The efficacy and the toxicity were evaluated according to RECIST 1.0 criteria and the NCI CTC 3.0 every 2 cycles. The survival status were followed up. Results Forty-five patients could be evaluated efficacy，and 46 patients could be evaluated adverse events. The respose rates（RR） were 31.6％ and 26.9％, and the disease control rates（DCR）were 68.4％ and 57.7％ in triplet regimen and doublet regimen group, respectively. The median time to tumor progression（TTP） were 5.2 months and 4.5 months and the median overall survive（OS） were 10.0 months and 9.1 months，respectively. The above differences were no statistical significance（P＞0.05）. Toxicity of two groups were tolerable. The major adverse events were grade 1/2 hematologic toxicity，and grade 3/4 were rare. The incidence of bone marrow suppression，catarrh and fatigue were lower in doublet regimen group than those in triple regimen group with significance difference. Conclusion Docetaxelcontaining doublet regimen as the firstline chemotherapy for advanced gastric cancer of Chinese patients has similar efficacy and better tolerance compared to triplet regimen. It deserves further clincal research.